HIV

Triple-drug regimen clears HIV in newborn primates, OHSU study finds

A one-time combination of three therapies administered within 72 hours of birth permanently cleared HIV infection in newborn primates, according to a study published in Nature Microbiology by researchers at Oregon Health & Science University. The findings, announced on August…

Gilead, Merck once-weekly HIV pill succeeds in Phase 3

Gilead Sciences and Merck announced on Sunday that their investigational once-weekly combination pill of islatravir and lenacapavir met its primary efficacy endpoint in two Phase 3 trials, marking a potential milestone in HIV treatment as the first long-acting oral therapy…